Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.5.1.18 (
glutathione S-transferase
)
22,582
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mice with a homozygous knockout of the jumonji (jmj) gene showed abnormal heart development and defective regulation of cardiac-specific genes, including the atrial natriuretic factor (ANF). ANF is one of the earliest markers of cardiac differentiation and a hallmark for cardiac hypertrophy. Here, we show that
JMJ
represses ANF gene expression by inhibiting transcriptional activities of Nkx2.5 and GATA4.
JMJ
represses the Nkx2.5- or GATA4-dependent activation of the reporter genes containing the ANF promoter-enhancer or containing the Nkx2.5 or GATA4-binding consensus sequence.
JMJ
physically associates with Nkx2.5 and GATA4 in vitro and in vivo as determined by
glutathione S-transferase
pull-down and immunoprecipitation assays. Using mutational analyses, we mapped the protein-protein interaction domains in
JMJ
, Nkx2.5, and GATA4. We identified two DNA-binding sites of
JMJ
in the ANF enhancer by gel mobility shift assays. However, these
JMJ
-binding sites do not seem to mediate ANF repression by
JMJ
. Mutational analysis of
JMJ
indicates that the protein-protein interaction domain of
JMJ
mediates the repression of ANF gene expression. Therefore,
JMJ
may play important roles in the down-regulation of ANF gene expression and in heart development.
...
PMID:Jumonji represses atrial natriuretic factor gene expression by inhibiting transcriptional activities of cardiac transcription factors. 1554 26